K. Weigang-Köhler

1.4k total citations
13 papers, 555 citations indexed

About

K. Weigang-Köhler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, K. Weigang-Köhler has authored 13 papers receiving a total of 555 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in K. Weigang-Köhler's work include Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (5 papers) and Pancreatic and Hepatic Oncology Research (4 papers). K. Weigang-Köhler is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (5 papers) and Pancreatic and Hepatic Oncology Research (4 papers). K. Weigang-Köhler collaborates with scholars based in Germany, Switzerland and France. K. Weigang-Köhler's co-authors include J. Wanders, P. Fumoleau, Jan H.M. Schellens, Patrick Schöffski, Ursula Thyroff‐Friesinger, G. Greim, Martina Stauch, R. de Boer, H. Curé and Hanno Riess and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

K. Weigang-Köhler

13 papers receiving 541 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Weigang-Köhler Germany 11 401 222 113 112 83 13 555
Anatole Cessot France 12 328 0.8× 195 0.9× 137 1.2× 81 0.7× 42 0.5× 30 562
A. Amelsberg United States 13 619 1.5× 262 1.2× 301 2.7× 131 1.2× 117 1.4× 22 852
Michela Guardascione Italy 16 336 0.8× 195 0.9× 331 2.9× 209 1.9× 56 0.7× 37 847
Colin Germond Canada 12 500 1.2× 161 0.7× 214 1.9× 93 0.8× 58 0.7× 21 794
Antonin Schmitt France 15 274 0.7× 118 0.5× 208 1.8× 52 0.5× 31 0.4× 48 557
Yu‐Li Su Taiwan 15 247 0.6× 172 0.8× 147 1.3× 103 0.9× 218 2.6× 75 637
Joline S.W. Lind Netherlands 14 276 0.7× 315 1.4× 184 1.6× 59 0.5× 34 0.4× 20 656
Motohiro Yamamori Japan 18 212 0.5× 156 0.7× 252 2.2× 103 0.9× 109 1.3× 42 655
Seng Chuan Tang Netherlands 12 380 0.9× 148 0.7× 244 2.2× 50 0.4× 33 0.4× 15 582
Kyu-pyo Kim South Korea 12 473 1.2× 132 0.6× 112 1.0× 46 0.4× 268 3.2× 18 654

Countries citing papers authored by K. Weigang-Köhler

Since Specialization
Citations

This map shows the geographic impact of K. Weigang-Köhler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Weigang-Köhler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Weigang-Köhler more than expected).

Fields of papers citing papers by K. Weigang-Köhler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Weigang-Köhler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Weigang-Köhler. The network helps show where K. Weigang-Köhler may publish in the future.

Co-authorship network of co-authors of K. Weigang-Köhler

This figure shows the co-authorship network connecting the top 25 collaborators of K. Weigang-Köhler. A scholar is included among the top collaborators of K. Weigang-Köhler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Weigang-Köhler. K. Weigang-Köhler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Faivre, Sandrine, Anthony J. Olszanski, K. Weigang-Köhler, et al.. (2015). Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors. Investigational New Drugs. 33(6). 1206–1216. 11 indexed citations
2.
Bergmann, Lothar, Luise Maute, Gerhard Heil, et al.. (2014). A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer. European Journal of Cancer. 51(1). 27–36. 51 indexed citations
3.
Weikersthal, Ludwig Fischer von, Andreas Schalhorn, Martina Stauch, et al.. (2010). Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer. European Journal of Cancer. 47(2). 206–214. 43 indexed citations
4.
Hanauske, A.-R., Michael Lahn, Luna Musib, et al.. (2009). Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. Annals of Oncology. 20(9). 1565–1575. 21 indexed citations
5.
Weigang-Köhler, K., et al.. (2009). HX575, Recombinant Human Epoetin Alfa, for the Treatment of Chemotherapy-Associated Symptomatic Anaemia in Patients with Solid Tumours. Oncology Research and Treatment. 32(4). 168–174. 32 indexed citations
6.
Hanauske, Axel-Rainer, Luna Musib, K. Weigang-Köhler, et al.. (2007). Comparison of enzastaurin pharmacokinetics and safety in the once daily (QD) and twice daily (BID) dose regimens: A phase I study. Journal of Clinical Oncology. 25(18_suppl). 14021–14021. 1 indexed citations
7.
Boeck, Stefan, K. Weigang-Köhler, Martin Fuchs, et al.. (2007). Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Annals of Oncology. 18(4). 745–751. 59 indexed citations
8.
Hanauske, Axel-Rainer, K. Weigang-Köhler, Bart C. Kuenen, et al.. (2006). 64 POSTER Phase I study of pemetrexed followed by daily enzastaurin in patients with advanced or metastatic cancer. European Journal of Cancer Supplements. 4(12). 23–24. 1 indexed citations
9.
Riess, Hanno, A. Helm, Marco Niedergethmann, et al.. (2005). A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. Journal of Clinical Oncology. 23(16_suppl). LBA4009–LBA4009. 80 indexed citations
10.
Chollet, P., Patrick Schöffski, K. Weigang-Köhler, et al.. (2003). Phase II trial with S-1 in chemotherapy-naıve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). European Journal of Cancer. 39(9). 1264–1270. 88 indexed citations
11.
Brande, Jan Van den, Patrick Schöffski, Jan H.M. Schellens, et al.. (2003). EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. British Journal of Cancer. 88(5). 648–653. 67 indexed citations
12.
Greim, G., Markus Borner, K. Weigang-Köhler, et al.. (2002). Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. European Journal of Cancer. 38(8). 1072–1080. 57 indexed citations
13.
Sessa, Cristiana, K. Weigang-Köhler, Olivia Pagani, et al.. (2002). Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule. European Journal of Cancer. 38(18). 2388–2396. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anatole Cessot Breakdown of academic impact, for papers by A. Amelsberg Breakdown of academic impact, for papers by Michela Guardascione Breakdown of academic impact, for papers by Colin Germond Breakdown of academic impact, for papers by Antonin Schmitt Breakdown of academic impact, for papers by Yu‐Li Su Breakdown of academic impact, for papers by Joline S.W. Lind Breakdown of academic impact, for papers by Motohiro Yamamori Breakdown of academic impact, for papers by Seng Chuan Tang Breakdown of academic impact, for papers by Kyu-pyo Kim
Rankless by CCL
2026